Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb Envisions PureVision Lens For 30-Day Wear By 2001

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb plans to seek FDA approval for an extended 30-day wear indication for its PureVision silicone-hydrogel soft contact lens by 2001.

You may also be interested in...



B&L Gains PureVision Insight From Ciba Vision's Ophthalmic Panel Review

Bausch & Lomb's PureVision 30-day continuous wear contact lenses could undergo review by FDA's Ophthalmic Devices Panel as early as Sept. 20-21.

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

UsernamePublicRestriction

Register

MT011382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel